

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6341695

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MARIA PAULA CARRANZA SANDMEIER	09/02/2020
RECEIVING PARTY DATA	
Name:	GLAXOSMITHKLINE BIOLOGICALS S.A.
Street Address:	RUE DE L'INSTUT 89
City:	RIXENSART
State/Country:	BELGIUM
Postal Code:	B-1330
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16822340
CORRESPONDENCE DATA	
Fax Number:	(215)446-8145
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2154468144
Email:	IPDocket.IPDocket@icemiller.com
Correspondent Name:	REBEKAH L. SIGLER C/O ICE MILLER LLP
Address Line 1:	1735 MARKET STREET
Address Line 2:	SUITE 3450
Address Line 4:	PHILADELPHIA, PENNSYLVANIA 19103
ATTORNEY DOCKET NUMBER:	004852.11654/90US2
NAME OF SUBMITTER:	REBEKAH L. SIGLER
SIGNATURE:	/rls/
DATE SIGNED:	10/08/2020
Total Attachments: 4	
source=004852_11654_90US2_ExecutedDeclaration_AssignmentDocument_GSK#page1.tif	
source=004852_11654_90US2_ExecutedDeclaration_AssignmentDocument_GSK#page2.tif	
source=004852_11654_90US2_ExecutedDeclaration_AssignmentDocument_GSK#page5.tif	
source=004852_11654_90US2_ExecutedDeclaration_AssignmentDocument_GSK#page6.tif	

**INVENTOR'S COMBINED
DECLARATION (37 CFR 1.63) AND ASSIGNMENT
(Utility Patent Application)**

As a below-named inventor/assignor of a certain new and useful invention for which I have executed an application for Letters Patent entitled:

BIOCONJUGATES OF E. COLI O-ANTIGEN POLYSACCHARIDES, METHODS OF PRODUCTION THEREOF, AND METHODS OF USE THEREOF

DECLARATION

I hereby declare that:

This Declaration is directed to United States patent application number 16/822,340 filed on March 18, 2020.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this Declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

Note to Inventor: 37 C.F.R. § 1.63(e) states: "A person may not execute an oath or declaration for an application unless that person has reviewed and understands the contents of the application, including the claims, and is aware of the duty to disclose to the Office all information known to the person to be material to patentability as defined in § 1.56."

ASSIGNMENT

WHEREAS, I ("ASSIGNOR") desire/am obligated to assign to the below-named ASSIGNEE the invention identified above;

WHEREAS, ("ASSIGNEE"):

GlaxoSmithKline Biologicals S.A.
Rue de l'Institut 89
Rixensart, B-1330
BELGIUM

is desirous of acquiring the entire right, title and interest in and to the invention throughout the United States and the world, and all right, title and interest in, to and under any and all Letters Patent of the United States and all countries throughout the world resulting from the invention;

FOR GOOD and VALUABLE CONSIDERATION, the full receipt and sufficiency of which are hereby acknowledged, ASSIGNOR(S), intending to be legally bound, do hereby:

AUTHORIZE said ASSIGNEE, or its representatives to insert above the filing date and application number of the application when these are known;

SELL, ASSIGN, TRANSFER and CONVEY to ASSIGNEE the whole and entire right, title and interest for the United States and its possessions and territories and all foreign countries in and to the invention which is disclosed in the above-identified patent application, and, in and to any and all patent applications related thereto including, but not limited to, all provisionals, non-provisionals, divisionals, continuations, continuations-in-part, substitutes, reexaminations, reissues and all other applications for patent which have been or shall be filed in the United States and all foreign countries on the invention; all original, reissued and reexamined patents and extensions thereof which have been or shall be issued in the United States and all foreign countries on the invention to the full end of the term or terms for which the patent(s) may be granted, as fully and entirely as the same would have been held by the undersigned ASSIGNOR(S) had this Assignment not been made; and specifically including all rights of priority created by the above patent application under any treaty, convention or law relating thereto;

AUTHORIZE and REQUEST the issuing authority to issue any and all United States and foreign patents granted on the invention to ASSIGNEE;

WARRANT and REPRESENT that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been or will be made to others by ASSIGNOR(S), and that the full right to convey the same as herein expressed is possessed by ASSIGNOR(S);

AGREE and UNDERTAKE, when requested and at the expense of ASSIGNEE, to carry out in good faith the intent and purpose of this Assignment. ASSIGNOR(S) will execute all non-provisionals, divisionals, continuations, continuations-in-part, substitutes, reexaminations, reissues, and all other patent applications on the invention; execute all lawful oaths, declarations, assignments, powers of attorney and other papers; communicate to ASSIGNEE all facts known to ASSIGNOR(S) relating to the invention and the history thereof; and generally do everything possible which ASSIGNEE shall consider desirable for vesting title to the invention in ASSIGNEE, and for securing, maintaining and enforcing proper patent protection for the invention; all without further compensation to ASSIGNOR(S);

TO BE BINDING on the heirs, assigns, representatives and successors of ASSIGNOR(S) and extending to the successors, assigns, and nominees of ASSIGNEE.

Thirteenth Joint Inventor/Assignor:

Date: 02.09.2020

Signature:



Typed Legal Name:

Maria Paula CARRANZA SANDMEIER

GlaxoSmithKline Biologicals S.A. hereby acknowledges and accepts this assignment and the full right, title and interest in and to said invention and said Patent Application.

GlaxoSmithKline Biologicals S.A. (Assignee)

30-9-2020
Date

Marcus J. Dalton
Signature

MARCUS J. W. DALTON
Typed or Printed Name

ATTORNEY & AUTHORIZED OFFICIAL
Title

MAE
Witness

30.9.2020
Date

[Signature]
Witness

30-9-2020
Date